Abcam, ab108746, Human Anti-Influenza virus B IgG ELISA Kit

Size: 1 x 96Tests
Human Anti-Influenza virus B IgG ELISA Kit is an indirect ELISA for the qualitative detection of IgG class antibodies against Influenza virus B in human plasma and serum samples. - Colorimetric readout - 450 nm - Works on any standard plate reader - Easy results interpretation - Cut-off, positive and negative controls included
Key facts
Detection method:Colorimetric,
Sample types:Citrate plasma, Heparin Plasma, Serum,
Reacts with:Human,
Assay type:Indirect,
Assay Platform:Microplate

Product details:
Abcam's anti-Influenza virus B IgG Human
in vitro
ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgG class antibodies against Influenza virus B in Human serum and plasma.
A 96-well plate has been precoated with Influenza virus B antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgG conjugate is added to the wells, which binds to the immobilized Influenza virus B-specific antibodies. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Influenza virus B IgG sample captured in plate.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Influenza B IgG also referred to as Flu B Antibodies are immunoglobulins targeting the Influenza B virus which is one of the two main types of influenza viruses that cause human flu epidemics. Influenza B viruses have a slower mutation rate compared to Influenza A but they can still cause significant seasonal outbreaks. These antibodies play an essential role in neutralizing the virus and curbing infection. They are expressed in the serum of individuals following infection or vaccination and their levels can be measured using techniques like ELISA test kits specifically designed for Influenza B antibody detection. The molecular mass of a typical IgG molecule is approximately 150 kDa.
Biological function summary
These antibodies are critical for the immune defense mechanism against the Influenza B virus. They are part of the larger immunoglobulin complex which is responsible for identifying and immobilizing pathogens. IgG antibodies against Influenza B target viral surface proteins such as hemagglutinin (HA) and neuraminidase (NA) which are essential for the virus's ability to infect host cells. This action assists in the prevention of the virus entering cells and propagating within the host.
Pathways
IgG antibodies against Influenza B are integral to the adaptive immune response. The antibodies function within the humoral immunity pathway working alongside proteins like B cell receptors and helper T cells to generate a specific response against the virus. This response is important for long-term immune memory and protection against future Influenza B infections. Interactions with proteins involved in the antigen presentation pathway are also noteworthy as they enhance the immune system's ability to target the Influenza B virus effectively.
IgG antibodies provide significant defense against influenza infections particularly those caused by the Influenza B virus. These influenza-related illnesses are characterized by symptoms such as fever cough sore throat and fatigue. The presence and efficacy of Influenza B IgG are vital for reducing the severity and duration of these symptoms. In some cases individuals with compromised immune systems show lower levels of these antibodies predisposing them to more severe influenza-related complications. The connection between influenza B IgG levels and proteins involved in immune deficiencies highlights the importance of robust antibody responses for effective disease prevention and management.